NTRK2 and Parkinson disease: Targeting of growth factors such as brain‐derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase type B (TrkB) by specific activators such as dopamine receptor agonists may attenuate PD neuropathology.11